There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vertex Pharmaceuticals (VRTX), Mersana Therapeutics Inc (MRSN) and AquaBounty Technologies Inc (AQB) with bullish sentiments.
Vertex Pharmaceuticals (VRTX)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Vertex Pharmaceuticals, with a price target of $220. The company’s shares closed yesterday at $175.45.
Fein noted:
“Valuation and risks to our investment thesis. Our price target of $220/share (up from $109/share), is based on an equally weighted composite of: (a) $218/share, as a 30x multiple of taxed and diluted FY26 GAAP EPS of $22.18 discounted back to and (b) an NPV of $223/share (discount rate 10.5%, terminal growth rate of 2.0%).”
According to TipRanks.com, Fein is a 5-star analyst with an average return of 8.3% and a 44.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
Vertex Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $206, representing a 17.4% upside. In a report issued on November 26, Barclays also maintained a Buy rating on the stock with a $200 price target.
.
See today’s analyst top recommended stocks >>
Mersana Therapeutics Inc (MRSN)
In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Mersana Therapeutics Inc, with a price target of $23. The company’s shares closed yesterday at $5.84, close to its 52-week low of $5.07.
Chattopadhyay observed:
“Our 12-month, $23 price target is based on a 13-year DCF-driven, sum-of-the-parts analysis. Our DCF is based on a: beta of 1.55, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.8%, and tax rate of 15% beginning in FY 2027. Our price target leverages the lifting of the partial clinical hold on XMT-1522, and we have added the program back into our model, albeit at modest probability of successes, including: (1) 5% POS in HER 1+/2+ breast cancer; and (2) 25% POS in the HER 2+ setting. Our rNPV for XMT-1522 [Takeda (TKPYY; not rated) owns ex-North America rights] is about $8/share.”
According to TipRanks.com, Chattopadhyay ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -7.8% and a 36.0% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Jounce Therapeutics Inc.
Currently, the analyst consensus on Mersana Therapeutics Inc is a Strong Buy with an average price target of $23, which is a 293.8% upside from current levels. In a report issued on November 13, Cowen & Co. also maintained a Buy rating on the stock.
.
AquaBounty Technologies Inc (AQB)
H.C. Wainwright analyst Kevin Dede reiterated a Buy rating on AquaBounty Technologies Inc today and set a price target of $3.75. The company’s shares closed yesterday at $2.39, close to its 52-week low of $2.25.
According to TipRanks.com, Dede is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -17.6% and a 26.2% success rate. Dede covers the Consumer Goods sector, focusing on stocks such as Top Image Systems, Microvision, and SuperCom.
AquaBounty Technologies Inc has an analyst consensus of Moderate Buy, with a price target consensus of $3.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
